340
Views
14
CrossRef citations to date
0
Altmetric
Research Article

Cost-effectiveness Analysis of Pegylated-liposomal Doxorubicin and Liposomal Daunorubicin Treatments in Patients with Kaposi's Sarcoma

Pages 1063-1067 | Published online: 08 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Karina Raimundo, Joseph Biskupiak, Michael Goodman, Scott Silverstein & Carl Asche. (2013) Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS–Kaposi’s sarcoma. Journal of Medical Economics 16:5, pages 606-613.
Read now
Rita Bosetti, Wim Marneffe & Lode Vereeck. (2013) Assessing The Need for Quality-Adjusted Cost–Effectiveness Studies of Nanotechnological Cancer Therapies. Nanomedicine 8:3, pages 487-497.
Read now
Russell Becker, Carole Dembek, Leigh Ann White & Louis P Garrison. (2012) The cost offsets and cost–effectiveness associated with pegylated drugs: a review of the literature. Expert Review of Pharmacoeconomics & Outcomes Research 12:6, pages 775-793.
Read now
Francesca Cainelli & Alfredo Vallone. (2009) Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma. Biologics: Targets and Therapy 3, pages 385-390.
Read now
Christin E Petre & Dirk P Dittmer. (2007) Liposomal daunorubicin as treatment for Kaposi’s sarcoma. International Journal of Nanomedicine 2:3, pages 277-288.
Read now
Tazio Vanni, Benedito Antonio Lopes Fonseca & Carisi Anne Polanczyk. (2006) Cost-Effectiveness Analysis Comparing Chemotherapy Regimens in the Treatment of AIDS-Related Kaposi’s Sarcoma in Brazil. HIV Clinical Trials 7:4, pages 194-202.
Read now

Articles from other publishers (8)

M. H. Li, H. Yu, T. F. Wang, N. D. Chang, J. Q. Zhang, D. Du, M. F. Liu, S. L. Sun, R. Wang, H. Q. Tao, S. L. Geng, Z. Y. Shen, Q. Wang & H. S. Peng. (2014) Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo. Journal of Materials Chemistry B 2:12, pages 1619.
Crossref
Karina Pupio Raimundo & Carl V. Asche. (2011) A review of the efficacy and outcomes studies of currently approved chemotherapy treatments for advanced AIDS-Kaposi's sarcoma. HIV & AIDS Review 10:3, pages 56-60.
Crossref
Valesca P. Retèl, Marjan J.M. Hummel & Wim H. van Harten. (2009) Review on early technology assessments of nanotechnologies in oncology. Molecular Oncology 3:5-6, pages 394-401.
Crossref
Charles L. Bennett & Elizabeth A. Calhoun. (2004) Pharmacoeconomics of liposomal anthracycline therapy. Seminars in Oncology 31, pages 191-195.
Crossref
Paul T Martinelli & Stephen K Tyring. (2002) Human herpesvirus 8. Dermatologic Clinics 20:2, pages 307-314.
Crossref
U.R Hengge, S Esser, H.-P Rudel & M Goos. (2001) Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. European Journal of Cancer 37:7, pages 878-883.
Crossref
M.R. Ranson, S. Cheeseman, S. White & J. Margison. (2001) Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Critical Reviews in Oncology/Hematology 37:2, pages 115-120.
Crossref
Pierre Vierling, Catherine Santaella & Jacques Greiner. (2001) Highly fluorinated amphiphiles as drug and gene carrier and delivery systems. Journal of Fluorine Chemistry 107:2, pages 337-354.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.